全文获取类型
收费全文 | 1022篇 |
免费 | 55篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 72篇 |
妇产科学 | 5篇 |
基础医学 | 136篇 |
口腔科学 | 46篇 |
临床医学 | 115篇 |
内科学 | 195篇 |
皮肤病学 | 22篇 |
神经病学 | 50篇 |
特种医学 | 186篇 |
外科学 | 68篇 |
综合类 | 26篇 |
预防医学 | 66篇 |
眼科学 | 16篇 |
药学 | 50篇 |
中国医学 | 2篇 |
肿瘤学 | 45篇 |
出版年
2023年 | 3篇 |
2022年 | 12篇 |
2021年 | 13篇 |
2020年 | 11篇 |
2019年 | 16篇 |
2018年 | 23篇 |
2017年 | 13篇 |
2016年 | 22篇 |
2015年 | 25篇 |
2014年 | 24篇 |
2013年 | 37篇 |
2012年 | 39篇 |
2011年 | 33篇 |
2010年 | 50篇 |
2009年 | 47篇 |
2008年 | 41篇 |
2007年 | 38篇 |
2006年 | 32篇 |
2005年 | 45篇 |
2004年 | 21篇 |
2003年 | 7篇 |
2002年 | 14篇 |
2001年 | 18篇 |
2000年 | 11篇 |
1999年 | 23篇 |
1998年 | 51篇 |
1997年 | 47篇 |
1996年 | 49篇 |
1995年 | 34篇 |
1994年 | 40篇 |
1993年 | 36篇 |
1992年 | 12篇 |
1991年 | 15篇 |
1990年 | 10篇 |
1989年 | 27篇 |
1988年 | 43篇 |
1987年 | 20篇 |
1986年 | 16篇 |
1985年 | 29篇 |
1984年 | 8篇 |
1983年 | 2篇 |
1982年 | 6篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1976年 | 12篇 |
1975年 | 3篇 |
1971年 | 1篇 |
排序方式: 共有1113条查询结果,搜索用时 15 毫秒
21.
22.
23.
Results of randomized controlled trials of low-versus high-osmolality contrast media 总被引:1,自引:0,他引:1
The authors reviewed 100 randomized controlled trials (RCTs) conducted in humans to compare safety or efficacy of new low-osmolality contrast media (LOM) with that of high-osmolality contrast media (HOM). Findings of the 43 RCTs judged to be of the highest quality suggest that the efficacy of LOM in imaging is equal or superior to that of HOM for all routes of administration. Heat sensation occurred less often with LOM for all routes and pain occurred less often with LOM for intraarterial routes. No differences were seen in nephrotoxicity or in frequency of nausea, vomiting, urticaria, bronchospasm, laboratory test abnormalities, or neurologic events. Greater cardiovascular changes were seen with HOM, including increased or decreased heart rate, increased left ventricular end-diastolic pressure, decreased systolic pressure, and QT prolongation, depending on route of administration. To demonstrate whether a reduction in clinically significant adverse outcomes truly occurs with LOM, trials will need to enlist larger numbers of patients and employ appropriate outcome measures. Future trials should stratify patients according to their risk of adverse reactions to provide better information about benefits of LOM in low- versus high-risk patients. 相似文献
24.
25.
26.
Intra-arterial tissue adhesive for medical splenectomy in humans 总被引:2,自引:0,他引:2
27.
Paul T Kr ner Megan ML Engels Benjamin S Glicksberg Kipp W Johnson Obaie Mzaik Jeanin E van Hooft Michael B Wallace Hashem B El-Serag Chayakrit Krittanawong 《World journal of gastroenterology : WJG》2021,27(40):6794-6824
The development of artificial intelligence (AI) has increased dramatically in the last 20 years, with clinical applications progressively being explored for most of the medical specialties. The field of gastroenterology and hepatology, substantially reliant on vast amounts of imaging studies, is not an exception. The clinical applications of AI systems in this field include the identification of premalignant or malignant lesions (e.g., identification of dysplasia or esophageal adenocarcinoma in Barrett’s esophagus, pancreatic malignancies), detection of lesions (e.g., polyp identification and classification, small-bowel bleeding lesion on capsule endoscopy, pancreatic cystic lesions), development of objective scoring systems for risk stratification, predicting disease prognosis or treatment response [e.g., determining survival in patients post-resection of hepatocellular carcinoma), determining which patients with inflammatory bowel disease (IBD) will benefit from biologic therapy], or evaluation of metrics such as bowel preparation score or quality of endoscopic examination. The objective of this comprehensive review is to analyze the available AI-related studies pertaining to the entirety of the gastrointestinal tract, including the upper, middle and lower tracts; IBD; the hepatobiliary system; and the pancreas, discussing the findings and clinical applications, as well as outlining the current limitations and future directions in this field. 相似文献
28.
29.
30.
Huizhen Wang Melissa Larson Albina Jablonka-Shariff Christopher A. Pearl William L. Miller P. Michael Conn Irving Boime T. Rajendra Kumar 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(15):5735-5740
FSH and luteinizing hormone (LH) are secreted constitutively or in pulses, respectively, from pituitary gonadotropes in many vertebrates, and regulate ovarian function. The molecular basis for this evolutionarily conserved gonadotropin-specific secretion pattern is not understood. Here, we show that the carboxyterminal heptapeptide in LH is a gonadotropin-sorting determinant in vivo that directs pulsatile secretion. FSH containing this heptapeptide enters the regulated pathway in gonadotropes of transgenic mice, and is released in response to gonadotropin-releasing hormone, similar to LH. FSH released from the LH secretory pathway rescued ovarian defects in Fshb-null mice as efficiently as constitutively secreted FSH. Interestingly, the rerouted FSH enhanced ovarian follicle survival, caused a dramatic increase in number of ovulations, and prolonged female reproductive lifespan. Furthermore, the rerouted FSH vastly improved the in vivo fertilization competency of eggs, their subsequent development in vitro and when transplanted, the ability to produce offspring. Our study demonstrates the feasibility to fine-tune the target tissue responses by modifying the intracellular trafficking and secretory fate of a pituitary trophic hormone. The approach to interconvert the secretory fate of proteins in vivo has pathophysiological significance, and could explain the etiology of several hormone hyperstimulation and resistance syndromes.During vertebrate evolution, the female reproductive pattern underwent a remarkable transition from spawning of large number of eggs in primitive species under favorable conditions to more tightly controlled ovarian cycles in higher vertebrates, such that only a limited number (rodents) or a single (human and nonhuman primates) egg is released per cycle (1, 2). Coincident with this event, the single pituitary gonadotropic hormone that exists in primitive vertebrates has given rise to two gonadotropins, FSH and luteinizing hormone (LH), which coordinate gametogenesis and steroidogenesis (3–7). FSH and LH are heterodimeric glycoproteins that contain a common α-subunit and a hormone-specific β-subunit (3). Although synthesized in the same cell, the gonadotrope, FSH is mostly constitutively released in many species, whereas LH is stored in dense core granules (DCGs) and secreted in pulses via the regulated pathway in response to gonadotropin-releasing hormone (GnRH) (8, 9). Although this pattern is evolutionarily conserved, how distinct modes of gonadotropin secretion affect ovarian development and target cell responses remain unclear. Although models in which variations in secretion of gonadotropins have been achieved in vivo (10) and in vitro, including basolateral and apically polarized secretion (11), the in vivo consequences of altered mode of gonadotropin trafficking and release (constitutive vs. regulated) from pituitary are untested. We sought to identify why the two gonadotropins, LH and FSH, expressed in the same pituitary cell have evolved to exit via different routes to regulate ovarian physiology. 相似文献